Genprex Q2 net loss narrows 5% to $4.45 million year over year
GNPX•Cash position and runway guidance
Cash and cash equivalents totaled $15.15 million at June 30, 2026; net cash used in operating activities was $8.28 million.
Genprex estimated cash runway into the second half of 2027 while Acclaim-1 and Acclaim-3 continue enrolling; Acclaim-3 interim enrollment is targeted by the end of 2026.
Quarterly loss narrows as expenses shift
Genprex posted a net loss of $4.45 million for the three months ended June 30, 2026, narrowing 5% year over year.
Research and development expense rose 7% to $2.68 million, driven by higher diabetes preclinical work and biomarker research.
General and administrative costs fell 17% to $1.8 million on lower professional services and related expenses.
